Dirk Strumberg

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

Dirk Strumberg, Heike Richly, Ralf A. Hilger et al. · Journal of Clinical Oncology · 2004 · 871 citations · Full text

Medicine, Oncology, Pharmacology +16

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial

Michael Untch, Sibylle Loibl, Joachim Bischoff et al. · The Lancet Oncology · 2012 · 454 citations

Medicine, Oncology, Pharmacology +17

Intraperitoneal Chemotherapy of Peritoneal Carcinomatosis Using Pressurized Aerosol as an Alternative to Liquid Solution: First Evidence for Efficacy

Reinhold Kerb, Thomas E. Mürdter, Urs Giger-Pabst et al. · Annals of Surgical Oncology · 2013 · 378 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Conversion of Topoisomerase I Cleavage Complexes on the Leading Strand of Ribosomal DNA into 5′-Phosphorylated DNA Double-Strand Breaks by Replication Runoff

Dirk Strumberg, André A. Pilon, Melanie Smith et al. · Molecular and Cellular Biology · 2000 · 361 citations · Full text

Life Sciences, Molecular Biology, Oncology +12

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours

Ahmad Awada, Alain Hendlisz, Thierry Gil et al. · British Journal of Cancer · 2005 · 338 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +14